Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.

Beer PA, Cooke SL, Chang DK, Biankin AV.

Ann Oncol. 2019 Oct 26. pii: mdz392. doi: 10.1093/annonc/mdz392. [Epub ahead of print]

PMID:
31665210
2.

Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.

Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, Wouters VM, Roper J, Kendall TJ, Roxburgh CS, Horgan PG, Nixon C, Nourse C, Gunzer M, Clark W, Hedley A, Yilmaz OH, Rashid M, Bailey P, Biankin AV, Campbell AD, Adams DJ, Barry ST, Steele CW, Medema JP, Sansom OJ.

Cancer Cell. 2019 Sep 16;36(3):319-336.e7. doi: 10.1016/j.ccell.2019.08.003.

3.

Pancreatic Cancer: From Genome Discovery to PRECISION-Panc.

Dreyer SB, Jamieson NB, Morton JP, Sansom OJ, Biankin AV, Chang DK.

Clin Oncol (R Coll Radiol). 2019 Sep 12. pii: S0936-6555(19)30343-7. doi: 10.1016/j.clon.2019.08.007. [Epub ahead of print] No abstract available.

PMID:
31522943
4.

Prolactin Promotes Fibrosis and Pancreatic Cancer Progression.

Tandon M, Coudriet GM, Criscimanna A, Socorro M, Eliliwi M, Singhi AD, Cruz-Monserrate Z, Bailey P, Lotze MT, Zeh H, Hu J, Goffin V, Gittes GK, Biankin AV, Esni F.

Cancer Res. 2019 Oct 15;79(20):5316-5327. doi: 10.1158/0008-5472.CAN-18-3064. Epub 2019 Aug 8.

PMID:
31395607
5.

PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer.

Dreyer SB, Jamieson NB, Cooke SL, Valle JW, McKay CJ, Biankin AV, Chang DK.

Clin Oncol (R Coll Radiol). 2019 Aug 2. pii: S0936-6555(19)30291-2. doi: 10.1016/j.clon.2019.07.011. [Epub ahead of print] No abstract available.

PMID:
31378449
6.

Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications.

Martens S, Lefesvre P, Nicolle R, Biankin AV, Puleo F, Van Laethem JL, Rooman I.

Ann Oncol. 2019 Sep 1;30(9):1428-1436. doi: 10.1093/annonc/mdz181.

PMID:
31161208
7.

Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling.

Dreyer SB, Jamieson NB, Evers L, Duthie F, Cooke S, Marshall J, Beraldi D, Knight S, Upstill-Goddard R, Dickson EJ, Carter CR, McKay CJ, Biankin AV, Chang DK.

Chin Clin Oncol. 2019 Apr;8(2):16. doi: 10.21037/cco.2019.04.06.

8.

Molecular subtypes of pancreatic cancer.

Collisson EA, Bailey P, Chang DK, Biankin AV.

Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220. doi: 10.1038/s41575-019-0109-y. Review.

PMID:
30718832
9.

Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer.

Dreyer SB, Pinese M, Jamieson NB, Scarlett CJ, Colvin EK, Pajic M, Johns AL, Humphris JL, Wu J, Cowley MJ, Chou A, Nagrial AM, Chantrill L, Chin VT, Jones MD, Moran-Jones K, Carter CR, Dickson EJ, Samra JS, Merrett ND, Gill AJ, Kench JG, Duthie F, Miller DK, Cooke S, Aust D, Knösel T, Rümmele P, Grützmann R, Pilarsky C, Nguyen NQ, Musgrove EA, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative; Glasgow Precision Oncology Laboratory.

Ann Surg. 2018 Nov 30. doi: 10.1097/SLA.0000000000003143. [Epub ahead of print]

PMID:
30570546
10.

ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling.

Pinho AV, Van Bulck M, Chantrill L, Arshi M, Sklyarova T, Herrmann D, Vennin C, Gallego-Ortega D, Mawson A, Giry-Laterriere M, Magenau A, Leuckx G, Baeyens L, Gill AJ, Phillips P, Timpson P, Biankin AV, Wu J, Rooman I.

Nat Commun. 2018 Nov 30;9(1):5083. doi: 10.1038/s41467-018-07497-z.

11.

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.

Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF.

Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.

12.

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.

13.

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.

Sheahan AV, Biankin AV, Parish CR, Khachigian LM.

Oncotarget. 2018 Apr 20;9(30):21613-21627. doi: 10.18632/oncotarget.25085. eCollection 2018 Apr 20. Review.

14.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

15.

Chemotherapy and radiotherapy for advanced pancreatic cancer.

Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D.

Cochrane Database Syst Rev. 2018 Mar 20;3:CD011044. doi: 10.1002/14651858.CD011044.pub2. Review.

16.

Defining the molecular pathology of pancreatic body and tail adenocarcinoma.

Dreyer SB, Jamieson NB, Upstill-Goddard R, Bailey PJ, McKay CJ; Australian Pancreatic Cancer Genome Initiative, Biankin AV, Chang DK.

Br J Surg. 2018 Jan;105(2):e183-e191. doi: 10.1002/bjs.10772.

17.

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.

Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, Cowley MJ, Molloy TJ; Australian Pancreatic Cancer Genome Initiative (APGI), Waddell N, Johns A, Grimmond SM, Chang DK, Biankin AV, Sansom OJ, Morton JP, Grey ST, Cox TR, Turchini J, Samra J, Clarke SJ, Timpson P, Gill AJ, Pajic M.

Gut. 2018 Dec;67(12):2142-2155. doi: 10.1136/gutjnl-2017-315144. Epub 2017 Oct 28.

18.

The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma.

Cooke SL, Ennis D, Evers L, Dowson S, Chan MY, Paul J, Hirschowitz L, Glasspool RM, Singh N, Bell S, Day E, Kochman A, Wilkinson N, Beer P, Martin S, Millan D, Biankin AV, McNeish IA; Scottish Genomes Partnership.

Clin Cancer Res. 2017 Dec 15;23(24):7633-7640. doi: 10.1158/1078-0432.CCR-17-1789. Epub 2017 Sep 27.

19.

Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours.

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MCJ, Bruxner TJC, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Hiriyur Nagaraj S, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Vittoria Davì M, Landoni L, Malpaga A, Miotto M, Whitehall VLJ, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LMS, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative, Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM.

Nature. 2017 Oct 26;550(7677):548. doi: 10.1038/nature24026. Epub 2017 Sep 27.

PMID:
28953865
20.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
21.

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma.

Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA.

Nat Genet. 2017 Jun;49(6):825-833. doi: 10.1038/ng.3861. Epub 2017 May 8.

22.

Lost in translation: returning germline genetic results in genome-scale cancer research.

Johns AL, McKay SH, Humphris JL, Pinese M, Chantrill LA, Mead RS, Tucker K, Andrews L, Goodwin A, Leonard C, High HA, Nones K, Patch AM, Merrett ND, Pavlakis N, Kassahn KS, Samra JS, Miller DK, Chang DK, Pajic M; Australian Pancreatic Cancer Genome Initiative, Pearson JV, Grimmond SM, Waddell N, Zeps N, Gill AJ, Biankin AV.

Genome Med. 2017 Apr 28;9(1):41. doi: 10.1186/s13073-017-0430-4.

23.

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.

Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, Melenec P, Walters SN, Del Monte-Nieto G, Conway JR, Nobis M, Allam AH, McCloy RA, Currey N, Pinese M, Boulghourjian A, Zaratzian A, Adam AA, Heu C, Nagrial AM, Chou A, Steinmann A, Drury A, Froio D, Giry-Laterriere M, Harris NL, Phan T, Jain R, Weninger W, McGhee EJ, Whan R, Johns AL, Samra JS, Chantrill L, Gill AJ, Kohonen-Corish M, Harvey RP, Biankin AV; Australian Pancreatic Cancer Genome Initiative (APGI), Evans TR, Anderson KI, Grey ST, Ormandy CJ, Gallego-Ortega D, Wang Y, Samuel MS, Sansom OJ, Burgess A, Cox TR, Morton JP, Pajic M, Timpson P.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8504. doi: 10.1126/scitranslmed.aai8504.

24.

Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development.

Dreyer SB, Chang DK, Bailey P, Biankin AV.

Clin Cancer Res. 2017 Apr 1;23(7):1638-1646. doi: 10.1158/1078-0432.CCR-16-2411. Review.

25.

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.

Harris NLE, Vennin C, Conway JRW, Vine KL, Pinese M, Cowley MJ, Shearer RF, Lucas MC, Herrmann D, Allam AH, Pajic M, Morton JP; Australian Pancreatic Cancer Genome Initiative, Biankin AV, Ranson M, Timpson P, Saunders DN.

Oncogene. 2017 Jul 27;36(30):4288-4298. doi: 10.1038/onc.2017.63. Epub 2017 Mar 27.

26.

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.

Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR.

Br J Cancer. 2017 Apr 11;116(8):1021-1026. doi: 10.1038/bjc.2017.40. Epub 2017 Mar 14.

27.

The road to precision oncology.

Biankin AV.

Nat Genet. 2017 Feb 24;49(3):320-321. doi: 10.1038/ng.3796.

PMID:
28232728
28.

Whole-genome landscape of pancreatic neuroendocrine tumours.

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Nagaraj SH, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Davì MV, Landoni L, Malpaga A, Miotto M, Whitehall VL, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LM, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative, Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM.

Nature. 2017 Mar 2;543(7643):65-71. doi: 10.1038/nature21063. Epub 2017 Feb 15. Erratum in: Nature. 2017 Sep 27;:.

PMID:
28199314
29.

Mitochondrial mutations and metabolic adaptation in pancreatic cancer.

Hardie RA, van Dam E, Cowley M, Han TL, Balaban S, Pajic M, Pinese M, Iconomou M, Shearer RF, McKenna J, Miller D, Waddell N, Pearson JV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative, Sazanov L, Biankin AV, Villas-Boas S, Hoy AJ, Turner N, Saunders DN.

Cancer Metab. 2017 Jan 30;5:2. doi: 10.1186/s40170-017-0164-1. eCollection 2017.

30.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

31.

PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance.

Roy N, Takeuchi KK, Ruggeri JM, Bailey P, Chang D, Li J, Leonhardt L, Puri S, Hoffman MT, Gao S, Halbrook CJ, Song Y, Ljungman M, Malik S, Wright CV, Dawson DW, Biankin AV, Hebrok M, Crawford HC.

Genes Dev. 2016 Dec 15;30(24):2669-2683. doi: 10.1101/gad.291021.116.

32.

Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids.

Sharbeen G, McCarroll J, Liu J, Youkhana J, Limbri LF, Biankin AV, Johns A, Kavallaris M, Goldstein D, Phillips PA.

Neoplasia. 2016 Dec;18(12):753-764. doi: 10.1016/j.neo.2016.10.011. Epub 2016 Nov 24.

33.

Hypermutation In Pancreatic Cancer.

Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Hofmann O, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Gill AJ, Pearson JV, Grimmond SM, Waddell N, Biankin AV.

Gastroenterology. 2017 Jan;152(1):68-74.e2. doi: 10.1053/j.gastro.2016.09.060. Epub 2016 Nov 15.

PMID:
27856273
34.

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.

Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J.

Sci Rep. 2016 Oct 20;6:35848. doi: 10.1038/srep35848.

35.

Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions.

Pinho AV, Mawson A, Gill A, Arshi M, Warmerdam M, Giry-Laterriere M, Eling N, Lie T, Kuster E, Camargo S, Biankin AV, Wu J, Rooman I.

Oncotarget. 2016 Nov 15;7(46):74768-74778. doi: 10.18632/oncotarget.11013.

36.

GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.

Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B Jr, Dusetti N, Greenhalf W, Rinaldi L, Costello E, Ghaneh P, Malats N, Büchler M, Pajic M, Biankin AV, Iovanna J, Neoptolemos J, Real FX.

Gut. 2017 Sep;66(9):1665-1676. doi: 10.1136/gutjnl-2015-311256. Epub 2016 Jun 20.

37.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ, Morton JP.

Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub 2016 Jun 2.

38.

Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling.

Humphrey ES, Su SP, Nagrial AM, Hochgräfe F, Pajic M, Lehrbach GM, Parton RG, Yap AS, Horvath LG, Chang DK, Biankin AV, Wu J, Daly RJ.

Mol Cell Proteomics. 2016 Aug;15(8):2671-85. doi: 10.1074/mcp.M116.058313. Epub 2016 Jun 3.

39.

Pancreatic cancer.

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP.

Nat Rev Dis Primers. 2016 Apr 21;2:16022. doi: 10.1038/nrdp.2016.22. Review.

PMID:
27158978
40.

Diagnosis and Management of Hereditary Pancreatic Cancer.

Humphris JL, Biankin AV.

Recent Results Cancer Res. 2016;205:61-83. doi: 10.1007/978-3-319-29998-3_5.

PMID:
27075349
41.

Genomic analyses identify molecular subtypes of pancreatic cancer.

Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM; Australian Pancreatic Cancer Genome Initiative, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM.

Nature. 2016 Mar 3;531(7592):47-52. doi: 10.1038/nature16965. Epub 2016 Feb 24.

PMID:
26909576
42.

Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.

Gingras MC, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N, Fisher WE; Australian Pancreatic Cancer Genome Initiative, Pilarsky C, Grützmann R, Overman MJ, Jamieson NB, Van Buren G 2nd, Drummond J, Walker K, Hampton OA, Xi L, Muzny DM, Doddapaneni H, Lee SL, Bellair M, Hu J, Han Y, Dinh HH, Dahdouli M, Samra JS, Bailey P, Waddell N, Pearson JV, Harliwong I, Wang H, Aust D, Oien KA, Hruban RH, Hodges SE, McElhany A, Saengboonmee C, Duthie FR, Grimmond SM, Biankin AV, Wheeler DA, Gibbs RA.

Cell Rep. 2016 Feb 2;14(4):907-919. doi: 10.1016/j.celrep.2015.12.005. Epub 2016 Jan 21.

43.

Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.

Pothula SP, Xu Z, Goldstein D, Biankin AV, Pirola RC, Wilson JS, Apte MV.

Br J Cancer. 2016 Feb 2;114(3):269-80. doi: 10.1038/bjc.2015.478. Epub 2016 Jan 14.

44.

A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas.

Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, Brosens LA, Fukushima N, Goggins M, Hruban RH, Kato Y, Klimstra DS, Klöppel G, Krasinskas A, Longnecker DS, Matthaei H, Offerhaus GJ, Shimizu M, Takaori K, Terris B, Yachida S, Esposito I, Furukawa T; Baltimore Consensus Meeting.

Am J Surg Pathol. 2015 Dec;39(12):1730-41. doi: 10.1097/PAS.0000000000000533.

45.

The Challenges of Precision Oncology Drug Development and Implementation.

Hollingsworth SJ, Biankin AV.

Public Health Genomics. 2015;18(6):338-48. doi: 10.1159/000441557. Epub 2015 Nov 11.

PMID:
26555355
46.

Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities.

Chin VT, Nagrial AM, Chou A, Biankin AV, Gill AJ, Timpson P, Pajic M.

Expert Rev Mol Med. 2015 Oct 28;17:e17. doi: 10.1017/erm.2015.17. Review.

47.

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials.

Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, Yip D.

Crit Rev Oncol Hematol. 2015 Dec;96(3):483-97. doi: 10.1016/j.critrevonc.2015.07.007. Epub 2015 Jul 26. Review.

PMID:
26481952
48.

Patient-centric trials for therapeutic development in precision oncology.

Biankin AV, Piantadosi S, Hollingsworth SJ.

Nature. 2015 Oct 15;526(7573):361-70. doi: 10.1038/nature15819. Review.

PMID:
26469047
49.

Subtyping Pancreatic Cancer.

Biankin AV, Maitra A.

Cancer Cell. 2015 Oct 12;28(4):411-413. doi: 10.1016/j.ccell.2015.09.020.

50.

Cancer Genetics and Implications for Clinical Management.

Jamieson NB, Chang DK, Biankin AV.

Surg Clin North Am. 2015 Oct;95(5):919-34. doi: 10.1016/j.suc.2015.05.003. Epub 2015 Jun 23. Review.

PMID:
26315514

Supplemental Content

Loading ...
Support Center